Hims & Hers Review

Score Breakdown

What They Offer

Hims & Hers is a consumer telehealth platform that expanded into weight loss and, after partnering with Novo Nordisk and Eli Lilly in 2026, shifted entirely from compounded semaglutide to brand-name FDA-approved GLP-1s: Wegovy (pill and pen), Ozempic (pill and injection), Zepbound (vial and KwikPen via LillyDirect), and Foundayo. The platform is built for speed — most patients get approved and receive a first shipment within days of the online intake — but the pricing structure separates the medication price from a required membership fee, and that split is easy to miss on a glance at the homepage.

How Much Hims & Hers Actually Costs

The direct answer: $298/mo minimum, not $149/mo. Every medication price on Hims & Hers' site is medication-only — a $149/mo Weight Loss Membership (billed at $39 for the first month, then $149/mo) is required on top of it, billed as a separate charge, before any prescription is filled.

Our verified pricing record (methodology) puts the lowest realistic monthly total at $298 and the highest at $448 for the products above. Retail-priced Mounjaro and the Zepbound brand pen run separately, close to $1,899/mo, and sit outside this range.

What's Included

• Initial online consultation with a Hims & Hers physician
• Prescription for a brand-name GLP-1 (Wegovy, Ozempic, Zepbound, or Foundayo)
• Monthly telehealth follow-up visits
• Medication shipped directly to your home
• Prescription management and refills
• Access to the Hims & Hers mobile app
• Messaging with a healthcare provider (limited)

Eligibility

Is Hims & Hers Legit?

Yes, in the sense that matters most: Hims & Hers Health, Inc. is a real, publicly traded company (NYSE: HIMS) that dispenses genuine, FDA-approved medication through licensed providers. It is not a scam and readers who sign up do receive real prescriptions. That said, there is regulatory history a reader asking "is this legit" deserves to see, and most reviews of this company omit it.

Two FDA warning letters, September 9, 2025

The FDA's Center for Drug Evaluation and Research sent near-identical warning letters to both corporate brands on the same day: one addressed to Andrew Dudum, CEO, Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567, reviewing hims.com), and one addressed to Andrew Dudum, CEO, Hims & Hers Health, Inc. dba Hers (MARCS-CMS 716825, reviewing forhers.com — the domain this review's outbound link points to). Both letters objected to the same claims appearing on the companies' compounded-semaglutide product pages:

• "Same active ingredient as Ozempic and Wegovy" / "Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy"
• "Clinically proven ingredients"

The FDA's position: compounded drug products are not FDA-approved, so claiming they share an "active ingredient" with an approved drug implies an equivalence that does not exist. That makes the products misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act — an advertising-language violation. It is not a finding of contamination, a recall, a safety alert, or evidence of patient harm. Numerous compounded-GLP-1 telehealth companies received similar letters the same week.

Whether it applies to what you'd actually buy: no, not directly. The letters concerned compounded semaglutide specifically — a product line Hims & Hers has since discontinued entirely, replacing it with the brand-name, FDA-approved Wegovy, Ozempic, Zepbound and Foundayo covered in the pricing table above. The letters are still worth knowing, both as advertising-practice history and because the Hers letter concerns the exact domain (forhers.com) our link sends readers to. Read them yourself: FDA.gov — Hers letter, warning-letters/hims-hers-health-inc-dba-hers-716825-09092025 and FDA.gov — Hims letter.

Pending FTC lawsuit, filed July 29, 2026

The Federal Trade Commission, joined by the State of California and the Utah Division of Consumer Protection, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California (Case No. 3:26-cv-07871). The complaint alleges the company charges consumers for prescriptions almost immediately after an intake form is submitted — despite telling them they will first consult with a provider — enrolls consumers in recurring subscriptions before they can review or approve a prescription, made cancellation difficult to find by hiding the cancel option behind several steps, and shared consumers' sensitive health information with third-party advertising platforms including Meta and Snap despite privacy assurances. The FTC is seeking a permanent injunction, monetary relief and civil penalties.

What this is not: a settlement, an admission, or a proven finding. As the FTC's own release states, "the case will be decided by the court," and Hims & Hers has not been found liable for anything at the time of writing. What it is: a filed federal complaint, corroborated on Hims & Hers' own Better Business Bureau profile, which currently carries no numeric rating and lists the case under "Pending Government Action." That BBB profile separately notes that its complaint file — 4,333 complaints in the prior three years, per BBB's public count — concerns "issues with cancelling orders and refund requests," consistent with what the FTC alleges. Sources: FTC.gov press release, July 29, 2026 and BBB.org business profile.

Neither action concerns drug safety, contamination, or the clinical effectiveness of the medications themselves. Both concern the company's advertising language and billing practices — which is exactly the kind of thing worth knowing before you hand over a payment method during an online intake form.

Refunds and Cancellation: What the Terms Actually Say

Hims & Hers' Terms and Conditions make no promise tied to weight-loss results of any kind — there is no outcome-based commitment, and nothing is returned to you based on how much weight you do or do not lose. What the terms cover instead is billing:

Cancelling your Medication Plan does not cancel your Weight Loss Membership — that keeps renewing separately until you cancel it too. This two-step structure is the same mechanic the pending FTC complaint above describes as difficult for consumers to navigate.

Clinical Results & Effectiveness

Because Hims & Hers now dispenses only brand-name, FDA-approved GLP-1s, published trial data for those exact drugs legitimately describes what a member is taking — unlike compounded-drug sellers, where a brand-drug trial result does not transfer. Hers' own site cites a 71-week clinical trial of oral semaglutide 25mg (the Wegovy Pill it dispenses) reporting an average 13.6% body-weight reduction (NEJM, DOI 10.1056/NEJMoa2500969). The injectable formulations it prescribes have their own trial evidence: the STEP 1 trial found semaglutide 2.4mg (Wegovy Pen/Ozempic injection) produced an average 14.9% weight reduction at 68 weeks, and the SURMOUNT-1 trial found tirzepatide 15mg (Zepbound/Mounjaro) produced an average 20.9% weight reduction at 72 weeks. Individual results vary and none of these figures are Hims & Hers' own outcomes data — they describe the medications, not the telehealth service around them.

Customer Experience

Hims & Hers is valued for its speed and brand recognition. Its Better Business Bureau complaint history — separate from and consistent with the pending FTC allegations above — centers on difficulty cancelling orders and refund requests. We could not verify a specific star rating on Trustpilot or any other third-party review platform at the time of this review (the sites block automated verification), so we are not publishing one; check current reviews directly on Trustpilot or the BBB profile linked above before deciding.

Frequently Asked Questions

Our Verdict

Disclosures